Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance

Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt(IV) prodrug

(2018) Alessandra Curci et al.   INORGANICA CHIMICA ACTA

Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid

(2017) Awatif Rashed Z. Almotairy et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action

(2016) Raji Raveendran et al.   Chemical Science

Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action

(2015) Lili Ma et al.   CHEMICAL COMMUNICATIONS

Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate

(2015) Rosa Ferriero et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Phenylbutyrate increases activity of pyruvate dehydrogenase complex.

(2015) Rosa Ferriero et al.   Oncotarget

The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin

(2014) Rakesh K. Pathak et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells

(2014) Qinqin Cheng et al.   CHEMICAL COMMUNICATIONS

Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance

(2014) Wilma Neumann et al.   ChemMedChem

Pros and cons of bifunctional platinum(iv) antitumor prodrugs: two are (not always) better than one

(2014) Elisabetta Gabano et al.   DALTON TRANSACTIONS

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: How long the organic chain should be?

(2014) Ilaria Zanellato et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands

(2014) Vojtech Novohradsky et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

COX-2 as a target for cancer chemotherapy

(2014) Nilanjan Ghosh et al.   Pharmacological Reports

Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70

(2014) H Endo et al.   Cell Death & Disease

Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells

(2013) Manuela Alessio et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2

(2013) Olivier Peulen et al.   PLoS One

What do we know about the reduction of Pt(IV) pro-drugs?

(2012) Ezequiel Wexselblatt et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Tuning the Activity of Platinum(IV) Anticancer Complexes through Asymmetric Acylation

(2012) Chee Fei Chin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Conjugate of Pt(IV)–Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy

(2012) Jun Yang et al.   MOLECULAR PHARMACEUTICS

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects

(2011) Ana-Maria Florea et al.   Cancers

The status of platinum anticancer drugs in the clinic and in clinical trials

(2010) Nial J. Wheate et al.   DALTON TRANSACTIONS

Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate

(2009) Shanta Dhar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels

(2007) Marcel N.A. Bijman et al.   BIOCHEMICAL PHARMACOLOGY